AADI 2.11 Aadi Bioscience, Inc.
| Range: | 1.21-5.7 | Vol Avg: | 229781 | Last Div: | 0 | Changes: | -0.04 |
| Beta: | 0.37 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 16 2018 | Empoloyees: | 70 | ||
| CUSIP: | 00032Q104 | CIK: | 0001422142 | ISIN: | US00032Q1040 | Country: | US |
| CEO: | Mr. David J. Lennon Ph.D. | Website: | https://aadibio.com | ||||
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Stock Details
AADI 1.75
Aadi Bioscience downgraded to Neutral from Overweight at Piper Sandler
Joseph Catanzaro·Tue Aug 27 2024
Piper Sandler
AADI 1.5
Aadi Bioscience downgraded to Hold from Buy at Jefferies
Roger Song·Wed Aug 21 2024
Jefferies
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow